… -term growth in pharmaceuticals. Eli Lilly and Company (LLY) Expands U.S … US Food and Drug Administration granted Eli Lilly and Company Breakthrough Therapy Designation … for its ovarian cancer drug …

Veradermics (MANE) upsized its IPO at pricing to 15.08 million shares – up from 13.35 million shares in the prospectus – and priced the IPO at $17.00 – $1.00 above the top of its range – to raise $256.36 million on Tuesday night, Feb. 3, 2026. Veradermics’ …

… manufacturing hub for complex biological drugs, Union Finance Minister Nirmala Sitharaman … no new biological drug — even biosimilars of existing drugs — can be … , president and general manager of Eli Lilly and Company (India), said: “We also appreciate …

… effect later this year. While drug pricing agreements will initially bring … $131 million promoting its obesity drug Zepbound, up from $2 million … treatment Mounjaro. Novo Nordisk and Eli Lilly and Co. are both scheduled to report …

… ; CBS/AP Drugmaker Eli Lilly and Co. announced Friday plans to build … injectable drugs and devices, including producing weight-loss drug retatrutide, … once-a-week injectable drug that is still being … treatment Zepbound and diabetes drug Mounjaro, is in the …

… side effects or adverse drug reactions, reveals that there … safety profile of different drugs.' Eli Lilly and Company, the sole manufacturer of … officially linked to the drug in the UK. At … the benefits [of these drugs] outweigh the potential risks …

Eli Lilly & Co. plans to build a $3.5 billion pharmaceutical plant in the Lehigh Valley to expand manufacturing capacity for next-generation weight-loss medicines, the Indiana company announced Friday in Allentown. The decision by Lilly to build one of …

AstraZeneca Plc agreed to pay Chinese company CSPC Pharmaceutical Group Ltd. as much as $18.5 billion for its obesity drug candidates, as the British drugmaker tries to push into the growing weight-loss market. The agreement will see AstraZeneca pay $1.2 …

… Drug-device combination products—integrating therapeutic drugs … and Company, and Eli Lilly and Company continue to drive … . January 2025: Eli Lilly and Company received FDA approval … and strategic acquisitions. Eli Lilly and Company (US) ranks second …

The UK warned some patients have died of severe inflammation of the pancreas linked to obesity and diabetes drugs such as Eli Lilly & Co.’s Mounjaro and Novo Nordisk A/S’s Wegovy. Though the worst cases of pancreatitis were rare, the UK Medicines …